<DOC>
	<DOCNO>NCT01962363</DOCNO>
	<brief_summary>The purpose study evaluate effect EPI-743 patient Friedreich 's Ataxia point mutation</brief_summary>
	<brief_title>EPI-743 Friedreich 's Ataxia Point Mutations</brief_title>
	<detailed_description>The primary objective study investigate whether treatment EPI-743 discernible impact visual functionâ€”including visual acuity , visual field color vision well number functional subject/clinician-rated scale relevant treatment Friedreich 's ataxia , determine safety treatment EPI-743 .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienol , alpha</mesh_term>
	<criteria>1 . Diagnosis genetically confirm Friedreich 's ataxia point mutation . 2 . Visual acuity baseline 15 letter high contrast EDTRS four meter . 3 . FARS score 20 90 . 4 . Male female 18 65 year age . 5 . Agreement use contraception within reproductive year 6 . Hormone replacement therapy , use , must remain stable duration study . 7 . Willingness ability comply study procedure . 8 . Willingness ability arrive study site metropolitan area day prior evaluation . 9 . Abstention use dietary supplement nonprescribed medication least 30 day prior initiation treatment duration study . This would specifically include idebenone , Coenzyme Q10 vitamin E. 10 . Abstention food beverages bar fortify Coenzyme Q10 , vitamin E , super fortify functional food beverage least 30 day prior initiation treatment duration study . 11 . Abstention use investigative nonapproved drug within 30 day enrollment duration study . 12 . Subject swallow multiple size 0 capsule . 13 . Subject voluntarily sign IRB approve informed consent form participate study relevant aspect study explain discuss subject . 1 . Allergy EPI743 sesame oil nut . 2 . Clinically significant bleed condition abnormal PT/PTT INR ( INR &gt; two ; PTT &gt; twotimes normal ) . 3 . Liver insufficiency LFTs great threetimes upper normal limit screening . 4 . Renal insufficiency creatinine &gt; 1.5 screening . 5 . Fat malabsorption syndrome . 6 . Any respiratory chain disease mitochondria inborn error metabolism . 7 . Any ophthalmologic condition . 8 . Clinically significant cardiomyopathy ejection fraction &lt; 40 percent screening . 9 . Clinically significant arrhythmia within past two year require treatment . 10 . Surgery plan duration study , include followup . 11 . Pregnancy breastfeed . 12 . Anticoagulant therapy within 30 day enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Friedreich 's ataxia point mutation</keyword>
</DOC>